Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Risk Communication Advisory Cmte. Will Assess Pharmacy Leaflets’ Utility

Executive Summary

FDA's Risk Communication Advisory Committee will meet Feb. 26-27 to discuss how to improve the usability of consumer medical information leaflets distributed by pharmacies with prescription drugs

You may also be interested in...



Single Patient Drug Leaflet Logical, Complicated To Achieve - Woodcock

FDA officials are leaning toward a single document to inform patients about their medications, but whether and how that can be accomplished remain unanswered questions

Single Patient Drug Leaflet Logical, Complicated To Achieve - Woodcock

FDA officials are leaning toward a single document to inform patients about their medications, but whether and how that can be accomplished remain unanswered questions

FDA Prepares Prototypes Of Consumer Medical Information Options

Workshop in September will gather input on how to ensure patients understand both risks and benefits.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS050468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel